Portola, Bristol-Myers, Pfizer deal

Portola received a $50 million loan from Bristol-Myers and Pfizer to fund development of Portola’s AndexXa andexanet alfa as a Factor Xa antidote. The pharmas each contributed $25 million and will each be repaid through a low single-digit percentage of net sales of AndexXa, up to $60-$65 million...